Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

e risk that the sale of the company's pulmonary business assets to Novartis Pharmaceuticals Corporation may not close or the closing may be delayed, (v) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (vi) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates or complex commercial agreements. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Stephan Herrera, 415-488-7699

sherrera@nektar.com

Jennifer Ruddock, 650-631-4954

jruddock@nektar.com

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share information)

Unaudited Unaudited

Three-Months Ended Nine-Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue:

Product sales and royalties $9,474 $37,497 $28,855 $159,818

Contract research 11,965 18,824 32,977 47,436

Total revenue 21,439 56,321 61,832 207,254

Ope
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... intact cells to treat and cure disease is ... is hindered by the inability of doctors and scientists ... these cells in patients without resorting to invasive procedures, ... 17 in the online journal Magnetic Resonance in ... Diego School of Medicine, University of Pittsburgh and elsewhere ...
Breaking Medicine News(10 mins):Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2
... cycles, known as circadian rhythms, are important for proper ... health. Disruptions of circadian rhythms and sleep-wake cycles have ... study by Douglas Institute researchers unravels a possible basis ... of clock genes in multiple areas of the human ...
... April, 2011: In the context of rising levels of cardiovascular ... of Cardiology (ESC) announces that for the first time- the ... Asia Pacific Congress of Cardiology (APCC). The 18th edition ... Malaysia, from 5 to 8 May 2011. The ESC deputation ...
... producing large quantities of a much-needed new imaging agent for ... other diseases, and the first evidence that the material is ... oxide nanoparticle, which is inexpensive, and stays in the body ... in the Journal of the American Chemical Society . ...
... a compound derived from tobacco, reduced plaques associated with dementia ... disease, a study led by researchers at Bay Pines VA ... The findings are reported online in the Journal ... "We found a compound that protects neurons, prevents the progression ...
... research shows that high maternal viral load and co-infection ... factors associated with vertical transmission of the hepatitis C ... (CC) is associated independently with the spontaneous clearance of ... in the mother or children did not increase risk ...
... -- Global Bridges, a healthcare alliance for tobacco dependence ... the InterAmerican Heart Foundation (IAHF) in Dallas, Texas, announced ... for health care providers in Latin America on how ... developed in collaboration with several regional and global expert ...
Cached Medicine News:Health News:Researchers observe disruptions of daily rhythms in Alzheimer's patients' brains 2Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:Tobacco-derived compound prevents memory loss in Alzheimer's disease mice 2Health News:Severity of hepatitis C and HIV co-infection in mothers contribute to HCV transmission to child 2Health News:Health care alliance for tobacco dependence treatment launches training in Mexico 2Health News:Health care alliance for tobacco dependence treatment launches training in Mexico 3
(Date:9/19/2014)... 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... and approved all parts required to build nine ... to manufacture the new PCT-based instrument system.  The ... for shipment by mid-October and that additional Barozyme ... rate of about one per week thereafter.  ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Diagnostics, one of the leading providers of arrhythmia ... technology with cardiac care to provide leading edge ... eCardio with machine-to-machine (M2M) wireless data ... of cardiac patients. eCardio,s monitoring solution on cardiac ...
... and SEATTLE, Oct. 7 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) candidates for the ... today results from its randomized, placebo controlled clinical ... rhinitis. The results demonstrated that VTX-1463 significantly improved ...
Cached Medicine Technology:AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 2AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Delicate strong curved serrated tips. Serrated handle with dull finish....
Medicine Products: